Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropharmacology
2014 Oct 01;85:232-42. doi: 10.1016/j.neuropharm.2014.05.027.
Show Gene links
Show Anatomy links
Different oxysterols have opposing actions at N-methyl-D-aspartate receptors.
Linsenbardt AJ
,
Taylor A
,
Emnett CM
,
Doherty JJ
,
Krishnan K
,
Covey DF
,
Paul SM
,
Zorumski CF
,
Mennerick S
.
???displayArticle.abstract???
Oxysterols have emerged as important biomarkers in disease and as signaling molecules. We recently showed that the oxysterol 24(S)-hydroxycholesterol, the major brain cholesterol metabolite, potently and selectively enhances NMDA receptor function at a site distinct from other modulators. Here we further characterize the pharmacological mechanisms of 24(S)-hydroxycholesterol and its synthetic analog SGE201. We describe an oxysterol antagonist of this positive allosteric modulation, 25-hydroxycholesterol. We found that 24(S)-hydroxycholesterol and SGE201 primarily increased the efficacy of NMDAR agonists but did not directly gate the channel or increase functional receptor number. Rather than binding to a direct aqueous-accessible site, oxysterols may partition into the plasma membrane to access the NMDAR, likely explaining slow onset and offset kinetics of modulation. Interestingly, oxysterols were ineffective when applied to the cytosolic face of inside-out membrane patches or through a whole-cell pipette solution, suggesting a non-intracellular site. We also found that another natural oxysterol, 25-hydroxycholesterol, although exhibiting slight potentiation on its own, non-competitively and enantioselectively antagonized the effects of 24(S)-hydroxycholesterol analogs. In summary, we suggest two novel allosteric sites on NMDARs that separately modulate channel gating, but together oppose each other.
Akk,
Neurosteroid access to the GABAA receptor.
2005, Pubmed
Akk,
Neurosteroid access to the GABAA receptor.
2005,
Pubmed
Akwa,
The synthetic enantiomer of pregnenolone sulfate is very active on memory in rats and mice, even more so than its physiological neurosteroid counterpart: distinct mechanisms?
2001,
Pubmed
Biellmann,
Enantiomeric steroids: synthesis, physical, and biological properties.
2003,
Pubmed
Bielska,
Oxysterols as non-genomic regulators of cholesterol homeostasis.
2012,
Pubmed
Borovska,
Access of inhibitory neurosteroids to the NMDA receptor.
2012,
Pubmed
Borschel,
Gating reaction mechanism of neuronal NMDA receptors.
2012,
Pubmed
Chen,
Subtype-dependence of NMDA receptor channel open probability.
1999,
Pubmed
Chisari,
The sticky issue of neurosteroids and GABA(A) receptors.
2010,
Pubmed
Clark,
The effect of agonist concentration, membrane voltage and calcium on N-methyl-D-aspartate receptor desensitization.
1990,
Pubmed
Collingridge,
The NMDA receptor as a target for cognitive enhancement.
2013,
Pubmed
Colquhoun,
Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.
1998,
Pubmed
Covey,
ent-Steroids: novel tools for studies of signaling pathways.
2009,
Pubmed
Coyle,
Glutamate and schizophrenia: beyond the dopamine hypothesis.
2006,
Pubmed
Diczfalusy,
On the formation and possible biological role of 25-hydroxycholesterol.
2013,
Pubmed
Freemantle,
Analysis of oxysterols and cholesterol in prefrontal cortex of suicides.
2013,
Pubmed
Gale,
Side chain oxygenated cholesterol regulates cellular cholesterol homeostasis through direct sterol-membrane interactions.
2009,
Pubmed
Griffiths,
Analysis of oxysterols by electrospray tandem mass spectrometry.
2006,
Pubmed
Horak,
Molecular mechanism of pregnenolone sulfate action at NR1/NR2B receptors.
2004,
Pubmed
Huettner,
Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels.
1988,
Pubmed
Leoni,
Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid.
2013,
Pubmed
Leoni,
Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: candidate marker of brain health.
2013,
Pubmed
Liere,
Analysis of pregnenolone and dehydroepiandrosterone in rodent brain: cholesterol autoxidation is the key.
2009,
Pubmed
Lin,
Glutamate signaling in the pathophysiology and therapy of schizophrenia.
2012,
Pubmed
Linsenbardt,
Noncompetitive, voltage-dependent NMDA receptor antagonism by hydrophobic anions.
2013,
Pubmed
,
Xenbase
Lund,
cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain.
1999,
Pubmed
MacDonald,
Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones.
1991,
Pubmed
Majewska,
Pregnenolone-sulfate: an endogenous antagonist of the gamma-aminobutyric acid receptor complex in brain?
1987,
Pubmed
Mast,
Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.
2010,
Pubmed
Mennerick,
Passive and synaptic properties of hippocampal neurons grown in microcultures and in mass cultures.
1995,
Pubmed
Miller,
Potentiation of NMDA receptor currents by arachidonic acid.
1992,
Pubmed
Olivares,
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
2012,
Pubmed
Olney,
NMDA receptor hypofunction model of schizophrenia.
1999,
Pubmed
Olsen,
Perturbations of membrane structure by cholesterol and cholesterol derivatives are determined by sterol orientation.
2009,
Pubmed
Olsen,
Side-chain oxysterols: from cells to membranes to molecules.
2012,
Pubmed
Parnas,
Membrane lipid modulations remove divalent open channel block from TRP-like and NMDA channels.
2009,
Pubmed
Parsons,
Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).
1993,
Pubmed
Patneau,
Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors.
1990,
Pubmed
Paul,
The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors.
2013,
Pubmed
Porter,
Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease.
2010,
Pubmed
Ramirez,
Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain.
2008,
Pubmed
Reddy,
Neurosteroids: endogenous role in the human brain and therapeutic potentials.
2010,
Pubmed
Rosenmund,
Synaptic NMDA receptor channels have a low open probability.
1995,
Pubmed
Russell,
Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain.
2009,
Pubmed
Tong,
Synaptic desensitization of NMDA receptors by calcineurin.
1995,
Pubmed
Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed
Westover,
Synthesis of ent-25-hydroxycholesterol.
2006,
Pubmed
Wong,
Primary human astrocytes produce 24(S),25-epoxycholesterol with implications for brain cholesterol homeostasis.
2007,
Pubmed
Wu,
Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor.
1991,
Pubmed
